Efgartigimod, a rationally engineered molecule with high binding affinity for the neonatal Fc receptor (FcRn), represents an effective and well-tolerated therapeutic option for the management of autoimmune diseases (7, 26). Here, FCGRT is linked to autoimmune disease.